# Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy

> **NCT01401959** · PHASE2 · COMPLETED · sponsor: **SCRI Development Innovations, LLC** · enrollment: 127 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Eribulin
- **DRUG:** Trastuzumab

## Key facts

- **NCT ID:** NCT01401959
- **Lead sponsor:** SCRI Development Innovations, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09-23
- **Primary completion:** 2017-04-03
- **Final completion:** 2017-04-03
- **Target enrollment:** 127 (ACTUAL)
- **Last updated:** 2018-06-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01401959

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01401959, "Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT01401959. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*